{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:17:54Z","timestamp":1740107874627,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10157-021-02139-z","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T17:24:23Z","timestamp":1632504263000},"page":"154-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cyclosporine A C1.5 monitoring reflects the area under the curve in children with nephrotic syndrome: a single-center experience"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4287-979X","authenticated-orcid":false,"given":"Tomohiko","family":"Nishino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tomori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Mimaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"issue":"9","key":"2139_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/bdd.1967","volume":"36","author":"NR Srinivas","year":"2015","unstructured":"Srinivas NR. Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharm Drug Dispos. 2015;36(9):575\u201386. https:\/\/doi.org\/10.1002\/bdd.1967.","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"2139_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00007691-200202000-00008","volume":"24","author":"M Oellerich","year":"2002","unstructured":"Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit. 2002;24(1):40\u20136. https:\/\/doi.org\/10.1097\/00007691-200202000-00008.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2139_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-014-2813-8","volume":"30","author":"LT Weber","year":"2015","unstructured":"Weber LT. Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol. 2015;30(2):253\u201365. https:\/\/doi.org\/10.1007\/s00467-014-2813-8.","journal-title":"Pediatr Nephrol"},{"issue":"9 Suppl","key":"2139_CR4","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/00007890-200205151-00003","volume":"73","author":"G Levy","year":"2002","unstructured":"Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral CERiTG. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73(9 Suppl):S12\u20138. https:\/\/doi.org\/10.1097\/00007890-200205151-00003.","journal-title":"Transplantation"},{"issue":"6","key":"2139_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/00007691-199512000-00013","volume":"17","author":"BD Kahan","year":"1995","unstructured":"Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit. 1995;17(6):621\u20134. https:\/\/doi.org\/10.1097\/00007691-199512000-00013.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"2139_CR6","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1097\/00007890-199612270-00009","volume":"62","author":"P Keown","year":"1996","unstructured":"Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery J, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 1996;62(12):1744\u201352. https:\/\/doi.org\/10.1097\/00007890-199612270-00009.","journal-title":"Transplantation"},{"issue":"2","key":"2139_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00007691-200104000-00003","volume":"23","author":"OJ David","year":"2001","unstructured":"David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23(2):100\u201314. https:\/\/doi.org\/10.1097\/00007691-200104000-00003.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2139_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1034\/j.1600-6143.2002.020206.x","volume":"2","author":"International Neoral Renal Transplantation Study G","year":"2002","unstructured":"International Neoral Renal Transplantation Study G. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant. 2002;2(2):148\u201356. https:\/\/doi.org\/10.1034\/j.1600-6143.2002.020206.x.","journal-title":"Am J Transplant"},{"issue":"6","key":"2139_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1034\/j.1600-6143.2002.20609.x","volume":"2","author":"E David-Neto","year":"2002","unstructured":"David-Neto E, Araujo LM, Brito ZM, Alves CF, Lemos FC, Yagyu EM, et al. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant. 2002;2(6):546\u201350. https:\/\/doi.org\/10.1034\/j.1600-6143.2002.20609.x.","journal-title":"Am J Transplant"},{"issue":"2 Suppl","key":"2139_CR10","doi-asserted-by":"publisher","first-page":"465S","DOI":"10.1016\/j.transproceed.2003.12.039","volume":"36","author":"A Barama","year":"2004","unstructured":"Barama A, Sepandj F, Gough J, McKenna R. Correlation between Neoral 2 hours post-dose levels and histologic findings on surveillance biopsies. Transplant Proc. 2004;36(2 Suppl):465S-S467. https:\/\/doi.org\/10.1016\/j.transproceed.2003.12.039.","journal-title":"Transplant Proc"},{"issue":"2 Suppl","key":"2139_CR11","doi-asserted-by":"publisher","first-page":"420S","DOI":"10.1016\/j.transproceed.2004.01.054","volume":"36","author":"F Citterio","year":"2004","unstructured":"Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2 Suppl):420S-S425. https:\/\/doi.org\/10.1016\/j.transproceed.2004.01.054.","journal-title":"Transplant Proc"},{"issue":"2","key":"2139_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2215\/CJN.13071212","volume":"9","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Oba MS, Ito S, Hataya H, Tanaka R, et al. Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol. 2014;9(2):271\u20138. https:\/\/doi.org\/10.2215\/CJN.13071212.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2139_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1525-1594.2009.00838.x","volume":"34","author":"I Griveas","year":"2010","unstructured":"Griveas I, Visvardis G, Papadopoulou D, Nakopolou L, Karanikas E, Gogos K, et al. Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome. Artif Organs. 2010;34(3):234\u20137. https:\/\/doi.org\/10.1111\/j.1525-1594.2009.00838.x.","journal-title":"Artif Organs"},{"issue":"2","key":"2139_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10157-017-1444-3","volume":"22","author":"Y Kuroyanagi","year":"2018","unstructured":"Kuroyanagi Y, Gotoh Y, Kasahara K, Nagano C, Fujita N, Yamakawa S, et al. Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy. Clin Exp Nephrol. 2018;22(2):413\u20139. https:\/\/doi.org\/10.1007\/s10157-017-1444-3.","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"2139_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.6061\/clinics\/2012(10)12","volume":"67","author":"S Henriques Ldos","year":"2012","unstructured":"Henriques Ldos S, Matos Fde M, Vaisbich MH. Pharmacokinetics of cyclosporin-a microemulsion in children with idiopathic nephrotic syndrome. Clinics (Sao Paulo). 2012;67(10):1197\u2013202. https:\/\/doi.org\/10.6061\/clinics\/2012(10)12.","journal-title":"Clinics (Sao Paulo)"},{"issue":"6","key":"2139_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/ndt\/gfh803","volume":"20","author":"G Filler","year":"2005","unstructured":"Filler G. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored? Nephrol Dial Transplant. 2005;20(6):1032\u20134. https:\/\/doi.org\/10.1093\/ndt\/gfh803.","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"2139_CR17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2169\/internalmedicine.47.1088","volume":"47","author":"M Naito","year":"2008","unstructured":"Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med. 2008;47(18):1567\u201372. https:\/\/doi.org\/10.2169\/internalmedicine.47.1088.","journal-title":"Intern Med"},{"issue":"7","key":"2139_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00467-005-1844-6","volume":"20","author":"K Nozu","year":"2005","unstructured":"Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, et al. Cyclosporin A absorption profiles in children with nephrotic syndrome. Pediatr Nephrol. 2005;20(7):910\u20133. https:\/\/doi.org\/10.1007\/s00467-005-1844-6.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2139_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1592\/phco.25.1.52.55617","volume":"25","author":"T Kusaba","year":"2005","unstructured":"Kusaba T, Konno Y, Hatta S, Fujino T, Yasuda T, Miura H, et al. More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome. Pharmacotherapy. 2005;25(1):52\u20138. https:\/\/doi.org\/10.1592\/phco.25.1.52.55617.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2139_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10157-008-0112-z","volume":"13","author":"S Shirai","year":"2009","unstructured":"Shirai S, Yasuda T, Tsuchida H, Kuboshima S, Konno Y, Shima Y, et al. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. Clin Exp Nephrol. 2009;13(2):123\u20139. https:\/\/doi.org\/10.1007\/s10157-008-0112-z.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"2139_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00431-011-1633-0","volume":"171","author":"K Ushijima","year":"2012","unstructured":"Ushijima K, Uemura O, Yamada T. Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome. Eur J Pediatr. 2012;171(4):663\u20138. https:\/\/doi.org\/10.1007\/s00431-011-1633-0.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2139_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1440-1797.2007.00773.x","volume":"12","author":"A Takeda","year":"2007","unstructured":"Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, et al. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology (Carlton). 2007;12(2):197\u2013204. https:\/\/doi.org\/10.1111\/j.1440-1797.2007.00773.x.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2139_CR23","first-page":"3432","volume":"27","author":"J Ahlmen","year":"1995","unstructured":"Ahlmen J, Sundberg A, Gustavsson A, Strombom U. Decreased nephrotoxicity after the use of a microemulsion formulation of cyclosporine A compared to conventional solution. Transplant Proc. 1995;27(6):3432\u20133.","journal-title":"Transplant Proc"},{"issue":"9","key":"2139_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1097\/00007890-199911150-00023","volume":"68","author":"PF Halloran","year":"1999","unstructured":"Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68(9):1356\u201361. https:\/\/doi.org\/10.1097\/00007890-199911150-00023.","journal-title":"Transplantation"},{"issue":"6","key":"2139_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s001470050080","volume":"10","author":"M Melter","year":"1997","unstructured":"Melter M, Rodeck B, Kardorff R, Hoyer PF, Brodehl J. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. Transpl Int. 1997;10(6):419\u201325. https:\/\/doi.org\/10.1007\/s001470050080.","journal-title":"Transpl Int"},{"issue":"1","key":"2139_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00467-006-0300-6","volume":"22","author":"M Medeiros","year":"2007","unstructured":"Medeiros M, Perez-Urizar J, Mejia-Gaviria N, Ramirez-Lopez E, Castaneda-Hernandez G, Munoz R. Decreased cyclosporine exposure during the remission of nephrotic syndrome. Pediatr Nephrol. 2007;22(1):84\u201390. https:\/\/doi.org\/10.1007\/s00467-006-0300-6.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2139_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00007691-200408000-00012","volume":"26","author":"LT Weber","year":"2004","unstructured":"Weber LT, Armstrong VW, Shipkova M, Feneberg R, Wiesel M, Mehls O, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit. 2004;26(4):415\u201324. https:\/\/doi.org\/10.1097\/00007691-200408000-00012.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2139_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol. 2015;19(1):6\u201333. https:\/\/doi.org\/10.1007\/s10157-014-1030-x.","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"2139_CR29","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/clinchem\/45.9.1477","volume":"45","author":"CM Stein","year":"1999","unstructured":"Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999;45(9):1477\u201384.","journal-title":"Clin Chem"},{"issue":"3","key":"2139_CR30","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/ndt\/gfm632","volume":"23","author":"P Falck","year":"2008","unstructured":"Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, et al. Cinacalcet\u2019s effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant. 2008;23(3):1048\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfm632.","journal-title":"Nephrol Dial Transplant"},{"key":"2139_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-04983-3","author":"F Zotta","year":"2021","unstructured":"Zotta F, Vivarelli M, Emma F. Update on the treatment of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2021. https:\/\/doi.org\/10.1007\/s00467-021-04983-3.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2139_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","volume":"68","author":"K Mahalati","year":"1999","unstructured":"Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68(1):55\u201362. https:\/\/doi.org\/10.1097\/00007890-199907150-00011.","journal-title":"Transplantation"},{"issue":"1","key":"2139_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-004-1618-6","volume":"20","author":"S Rinaldi","year":"2005","unstructured":"Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G. Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol. 2005;20(1):25\u20139. https:\/\/doi.org\/10.1007\/s00467-004-1618-6.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"2139_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1432-2277.2005.00151.x","volume":"18","author":"B Nashan","year":"2005","unstructured":"Nashan B, Bock A, Bosmans JL, Budde K, Fijter H, Jaques B, et al. Use of neoral C monitoring: a European consensus. Transpl Int. 2005;18(7):768\u201378. https:\/\/doi.org\/10.1111\/j.1432-2277.2005.00151.x.","journal-title":"Transpl Int"},{"issue":"11","key":"2139_CR35","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1124\/dmd.31.11.1292","volume":"31","author":"CY Wu","year":"2003","unstructured":"Wu CY, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos. 2003;31(11):1292\u20135. https:\/\/doi.org\/10.1124\/dmd.31.11.1292.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"2139_CR36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/s1053-2498(02)00649-6","volume":"22","author":"JE Ray","year":"2003","unstructured":"Ray JE, Keogh AM, McLachlan AJ, Akhlaghi F. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant. 2003;22(7):715\u201322. https:\/\/doi.org\/10.1016\/s1053-2498(02)00649-6.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"2139_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/lt.20341","volume":"11","author":"SE Yantorno","year":"2005","unstructured":"Yantorno SE, Varela EB, Raffa SR, Descalzi VI, Gomez Carretero ML, Pirola DA, et al. How common is delayed cyclosporine absorption following liver transplantation? Liver Transpl. 2005;11(2):167\u201373. https:\/\/doi.org\/10.1002\/lt.20341.","journal-title":"Liver Transpl"},{"issue":"4","key":"2139_CR38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3109\/03602539709002246","volume":"29","author":"ET Morgan","year":"1997","unstructured":"Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4):1129\u201388. https:\/\/doi.org\/10.3109\/03602539709002246.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"2139_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1081\/dmr-100101906","volume":"31","author":"H Iber","year":"1999","unstructured":"Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, Morgan ET. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev. 1999;31(1):29\u201341. https:\/\/doi.org\/10.1081\/dmr-100101906.","journal-title":"Drug Metab Rev"},{"issue":"4","key":"2139_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1034\/j.1399-3046.2003.00077.x","volume":"7","author":"R Trompeter","year":"2003","unstructured":"Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant. 2003;7(4):282\u20138. https:\/\/doi.org\/10.1034\/j.1399-3046.2003.00077.x.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2139_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.ftd.0000183385.27394.e7","volume":"28","author":"U Christians","year":"2006","unstructured":"Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28(1):39\u201344. https:\/\/doi.org\/10.1097\/01.ftd.0000183385.27394.e7.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2139_CR42","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/00007890-199904270-00008","volume":"67","author":"D Grant","year":"1999","unstructured":"Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation. 1999;67(8):1133\u20137. https:\/\/doi.org\/10.1097\/00007890-199904270-00008.","journal-title":"Transplantation"},{"issue":"9","key":"2139_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2215\/CJN.01520209","volume":"4","author":"S Kengne-Wafo","year":"2009","unstructured":"Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol. 2009;4(9):1409\u201316. https:\/\/doi.org\/10.2215\/CJN.01520209.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2139_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00003088-200241020-00004","volume":"41","author":"M del Mar Fernandez De Gatta","year":"2002","unstructured":"del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2002;41(2):115\u201335. https:\/\/doi.org\/10.2165\/00003088-200241020-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2139_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.clinbiochem.2004.04.001","volume":"37","author":"M Oellerich","year":"2004","unstructured":"Oellerich M, Armstrong VW, Streit F, Weber L, Tonshoff B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem. 2004;37(6):424\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.04.001.","journal-title":"Clin Biochem"},{"issue":"2","key":"2139_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00003088-198611020-00002","volume":"11","author":"RJ Ptachcinski","year":"1986","unstructured":"Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986;11(2):107\u201332. https:\/\/doi.org\/10.2165\/00003088-198611020-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2139_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1034\/j.1399-3046.2000.00093.x","volume":"4","author":"PF Hoyer","year":"2000","unstructured":"Hoyer PF. Therapeutic drug monitoring of cyclosporin A: should we use the area under the concentration-time curve and forget trough levels? Pediatr Transplant. 2000;4(1):2\u20135. https:\/\/doi.org\/10.1034\/j.1399-3046.2000.00093.x.","journal-title":"Pediatr Transplant"},{"issue":"6","key":"2139_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00003088-199732060-00004","volume":"32","author":"GF Cooney","year":"1997","unstructured":"Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet. 1997;32(6):481\u201395. https:\/\/doi.org\/10.2165\/00003088-199732060-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2139_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/clpt.1994.62","volume":"55","author":"DG May","year":"1994","unstructured":"May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther. 1994;55(5):492\u2013500. https:\/\/doi.org\/10.1038\/clpt.1994.62.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2139_CR50","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1590\/s0100-879x2003001200006","volume":"36","author":"CG Machado","year":"2003","unstructured":"Machado CG, Calado RT, Garcia AB, Falcao RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz J Med Biol Res. 2003;36(12):1653\u20137. https:\/\/doi.org\/10.1590\/s0100-879x2003001200006.","journal-title":"Braz J Med Biol Res"},{"issue":"8","key":"2139_CR51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/adc.2005.080960","volume":"91","author":"S Fujinaga","year":"2006","unstructured":"Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006;91(8):666\u201370. https:\/\/doi.org\/10.1136\/adc.2005.080960.","journal-title":"Arch Dis Child"},{"issue":"9","key":"2139_CR52","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7754\/clin.lab.2015.150225","volume":"61","author":"B Toole","year":"2015","unstructured":"Toole B, Gechtman C, Dreier J, Kuhn J, Gutierrez MR, Barrett A, et al. Evaluation of the new cyclosporine and tacrolimus automated electrochemiluminescence immunoassays under field conditions. Clin Lab. 2015;61(9):1303\u201315. https:\/\/doi.org\/10.7754\/clin.lab.2015.150225.","journal-title":"Clin Lab"},{"issue":"3","key":"2139_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","volume":"14","author":"V Haufroid","year":"2004","unstructured":"Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147\u201354. https:\/\/doi.org\/10.1097\/00008571-200403000-00002.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"2139_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481\u2013508. https:\/\/doi.org\/10.2215\/CJN.04800908.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02139-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:32:23Z","timestamp":1642663943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02139-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"16 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Teikyo University Ethical Review Board for Medical and Health Research Involving Human Subjects (approval number 20-195-2). All procedures in studies involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study plan outline was presented on the Teikyo University website, where patients and their guardians could ask questions about the study and opt out from the use of their data. Informed consent to participate and publication was obtained on the before blood sampling. The study was explained to all patients and their parents\/guardians in plain language with explanatory documents, and written consent for participation in research and publication was obtained from the parents\/guardians of all subjects. At the same time, it was clarified that the parents\/guardians had the right to refuse participation and withdraw consent at will.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/Consent for publication"}}]}}